P. Searle

发表

Identification of multiple metal regulatory elements in mouse metallothionein-I promoter by assaying synthetic sequences

R. Palmiter, G. Stuart, P. Searle, 1985, Nature.

Vectors based on reducible polycations facilitate intracellular release of nucleic acids

P. Searle, Martin L Read, L. Seymour, 2003, The journal of gene medicine.

A 12-base-pair DNA motif that is repeated several times in metallothionein gene promoters confers metal regulation to a heterologous gene.

R. Palmiter, G. Stuart, P. Searle, 1984, Proceedings of the National Academy of Sciences of the United States of America.

Zinc dependent binding of a liver nuclear factor to metal response element MRE-a of the mouse metallothionein-I gene and variant sequences.

P. Searle, 1990, Nucleic acids research.

Improved titers of retroviral vectors from the human FLYRD18 packaging cell line in serum- and protein-free medium.

P. Searle, P. Gerin, M. Al‐Rubeai, 1999, Human gene therapy.

Immune enhancement of nitroreductase‐induced cytotoxicity: Studies using a bicistronic adenovirus vector

D. Kerr, I. McNeish, L. Young, 2003, International journal of cancer.

Gene Therapy: Development of Immunostimulatory Treatments for Cancer

P. Searle, M. Gilligan, P. Knox, 2000, Biotechnology & genetic engineering reviews.

Receptor Gene Transfer to Target Nasopharyngeal Carcinoma

P. Searle, E. Hui, A. Chan, 2015 .

Immunotherapy II: Antigens, receptors and costimulation

L. Young, P. Searle, 1996, Cancer and Metastasis Reviews.

Virus-directed enzyme prodrug therapy using CB1954.

D. Kerr, I. McNeish, P. Searle, 1999, Anti-Cancer Drug Design.

Rapid estrogen metabolism and vitellogenin gene expression in xenopus hepatocyte cultures

A. Wolffe, P. Searle, J. Tata, 1983, Molecular and Cellular Endocrinology.

E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954

W. Wilson, P. Searle, E. Hyde, 2009, British Journal of Cancer.

Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo

K. Twigger, S. Bhide, A. Melcher, 2008, Gene Therapy.

Structural and Mechanistic Studies of Escherichia coli Nitroreductase with the Antibiotic Nitrofurazone

S. White, P. Searle, R. Green, 2005, Journal of Biological Chemistry.

Late expression of nitroreductase in an oncolytic adenovirus sensitizes colon cancer cells to the prodrug CB1954.

R. Iggo, P. Searle, Ming‐Jen Chen, 2005, Human gene therapy.

The nitroreductase/CB1954 enzyme-prodrug system.

D. Kerr, P. Searle, N. Green, 2004, Methods in molecular medicine.

Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954.

S. White, P. Searle, C. Guise, 2003, Cancer research.

Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector‐mediated expression of E. coli nitroreductase

D. Kerr, I. McNeish, L. Young, 2000, International journal of cancer.

Sensitisation of human ovarian cancer cells to killing by the prodrug CB1954 following retroviral or adenoviral transfer of the E. coli nitroreductase gene.

D. Kerr, I. McNeish, C. Springer, 1998, Advances in experimental medicine and biology.

Metal regulatory elements of the mouse metallothionein-I gene.

R. Palmiter, G. Stuart, P. Searle, 1987, Experientia. Supplementum.

4-1BBL costimulation retrieves CD28 expression in activated T cells.

P. Searle, M. Jaberipour, M. Habib-Agahi, 2009, Cellular immunology.

Vitellogenin gene expression in male xenopus hepatocytes during primary and secondary stimulation with estrogen in cell cultures

P. Searle, J. Tata, 1981, Cell.

Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells.

P. Searle, M. Habib-Agahi, T. T. Phan, 2007, International immunology.

The 3D‐structure, kinetics and dynamics of the E. coli nitroreductase NfsA with NADP + provide glimpses of its catalytic mechanism

S. White, P. Searle, A. Christofferson, 2022, FEBS letters.

Combining gene and immunotherapy for prostate cancer

N. James, L. Young, P. Searle, 2008, Prostate Cancer and Prostatic Diseases.

Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954

D. Kerr, L. Young, P. Searle, 2000, Cancer Gene Therapy.

Gene therapy for gastrointestinal cancer

D. Kerr, J. Neoptolemos, L. Young, 1996 .

Adenoviral delivery of B7–1 (CD80) increases the immunogenicity of human ovarian and cervical carcinoma cells

D. Kerr, P. Searle, R. Barton, 1998, Gene Therapy.

Inhibition of NF-κB enhances the cytotoxicity of virus-directed enzyme prodrug therapy and oncolytic adenovirus cancer gene therapy

D. Kerr, P. Searle, D. Palmer, 2005, Gene Therapy.

Prostate-specific Antigen Promoter / Enhancer Driven Gene Therapy for Prostate Cancer : Construction and Testing of a Tissue-specific Adenovirus Vector 1

N. James, P. Searle, V. Mautner, 2000 .

Production of Retroviral Vectors for Gene Therapy with the Human Packaging Cell Line FLYRD18

P. Searle, P. Gerin, M. Al‐Rubeai, 1999, Biotechnology progress.

Synthesis and structure-activity relationships of nitrobenzyl phosphoramide mustards as nitroreductase-activated prodrugs.

P. Searle, B. Hall, S. Wilkinson, 2011, Bioorganic & medicinal chemistry letters.

Preferential T cell expansion by artificial antigen presenting cells expressing 4-1BBL alone or in combination with CD80 or CD86.

P. Searle, M. Jaberipour, M. Habib-Agahi, 2008, Iranian journal of immunology : IJI.

Adenovirus-mediated expression of dominant negative fibroblast growth factor (FGF) receptor 1 in thyroid cells blocks FGF effects and reduces goitrogenesis in mice.

J. Franklyn, H. Ueno, P. Searle, 2003, The Journal of clinical endocrinology and metabolism.

Synergistic anti-tumor effects of nitroreductase mutants and p53.

A. Ghaderi, P. Searle, M. Jaberipour, 2014, Journal of cancer research and therapeutics.

Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors.

D. Kerr, L. Young, P. Searle, 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus

I. McNeish, L. Young, P. Searle, 2010, Molecular Cancer.

Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene.

D. Kerr, J. Neoptolemos, C. Springer, 1997, Cancer gene therapy.

Improved Production of Retroviral Vectors Under Serum-Free Conditions for the Application of Gene Therapy

P. Searle, P. Gerin, M. Al‐Rubeai, 2002 .

Stomach cancer in transgenic mice expressing human papillomavirus type 16 early region genes from a keratin promoter.

P. Searle, J. Tinsley, D. Thomas, 1994, The Journal of general virology.

Characterisation of bacterial clones containing DNA sequences derived from Xenopus laevis vitellogenin mRNA.

J. Williams, P. Searle, D. F. Smith, 1979, Nucleic acids research.

Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.

P. Searle, Longqin Hu, Jiye Han, 2003, Journal of medicinal chemistry.

Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.

P. Searle, Longqin Hu, Jiye Han, 2006, Journal of medicinal chemistry.

Kinetic and structural characterisation of Escherichia coli nitroreductase mutants showing improved efficacy for the prodrug substrate CB1954.

S. White, P. Searle, C. Wrighton, 2007, Journal of molecular biology.

NITROREDUCTASE: A PRODRUG‐ACTIVATING ENZYME FOR CANCER GENE THERAPY

D. Kerr, N. James, S. White, 2004, Clinical and experimental pharmacology & physiology.

A Phase I/II Clinical Trial in Localized Prostate Cancer of an Adenovirus Expressing Nitroreductase with CB1984.

N. James, L. Young, P. Searle, 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954.

D. Kerr, D. Ferry, P. Searle, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Gene Therapy for Cancer: Prospects for the Treatment of Lung Tumours

D. Kerr, L. Young, P. Searle, 1999 .

Dilated heart failure in transgenic mice expressing the Epstein-Barr virus nuclear antigen-leader protein.

P. Searle, D. Huen, P. Kumar, 1993, The Journal of general virology.

Gene Therapy for Colorectal Cancer

D. Kerr, L. Young, P. Searle, 2002, BioDrugs.

Building a metal-responsive promoter with synthetic regulatory elements

R. Palmiter, G. Stuart, P. Searle, 1985, Molecular and cellular biology.

Expression of a human O6-alkylguanine-DNA-alkyltransferase cDNA in human cells and transgenic mice.

G. Margison, P. Potter, C. Fan, 1990, Nucleic acids research.

Viral gene therapy strategies: from basic science to clinical application

L. Young, P. Searle, V. Mautner, 2006, The Journal of pathology.

Gene therapy strategies for colon cancer.

D. Kerr, L. Young, P. Searle, 2000, Molecular medicine today.

Strategies for the isolation and purification of retroviral vectors for gene therapy.

G Braas, P F Searle, N K Slater, 1996, Bioseparation.

Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.

N. James, P. Searle, V. Mautner, 2000, Cancer research.

Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations.

P. Searle, M. Jaberipour, Longqin Hu, 2010, Biochemical pharmacology.

Abnormalities of epidermal differentiation associated with expression of the human papillomavirus type 1 early region in transgenic mice.

P. Searle, C. Fisher, J. Tinsley, 1992, The Journal of general virology.

Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenoviruses.

R. Alemany, M. Cascalló, P. Searle, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus–Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma

P. Searle, E. Hui, A. Chan, 2015, Cancer Immunology Research.

Human Leukocyte Antigen (HLA) A 1101- Restricted Epstein-Barr Virus–Specific T-cell ReceptorGeneTransfer toTargetNasopharyngeal Carcinoma

P. Searle, E. Hui, A. Chan, 2015 .

Long-term proliferation of functional human NK cells, with conversion of CD56dim NK cells to a CD56bright phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-12

P. Searle, Steven P Lee, R. Bhatt, 2012, Cancer Immunology, Immunotherapy.

Regulation, linkage, and sequence of mouse metallothionein I and II genes

R. Palmiter, G. Stuart, P. Searle, 1984, Molecular and cellular biology.

Direct positive selection for improved nitroreductase variants using SOS triggering of bacteriophage lambda lytic cycle

P. Searle, C. Guise, J. Grove, 2007, Gene Therapy.

Virus-directed enzyme prodrug therapy (VDEPT): A clinical trial of adenovirus-delivered nitroreductase (NTR) in combination with CB1954 in patients with primary or secondary liver cancer

D. Kerr, N. James, L. Young, 2005 .

Expression of a human 06-alkylguanine-DNA-alkyltransferase cDNA in human cells and transgenic mice

P. Potter, P. Searle, A. Watson, 2022 .

Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer.

John Ellis, Nicholas D James, D. Kerr, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Structure and Dynamics of Three Escherichia coli NfsB Nitro-Reductase Mutants Selected for Enhanced Activity with the Cancer Prodrug CB1954

S. White, P. Searle, J. L. Anderson, 2023, International journal of molecular sciences.

Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector

D. Kerr, G. Reynolds, J. Flavell, 2004, Gene Therapy.

Steady-state and stopped-flow kinetic studies of three Escherichia coli NfsB mutants with enhanced activity for the prodrug CB1954.

S. White, S. Daff, P. Searle, 2009, Biochemistry.

A clinical trial of virus-directed enzyme prodrug therapy (VDEPT) using adenovirus encoded nitroreductase (ntr) and CB1954 in patients with localized prostate cancer (PCa).

N. James, L. Young, P. Searle, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The structure of Escherichia coli nitroreductase complexed with nicotinic acid: three crystal forms at 1.7 A, 1.8 A and 2.4 A resolution.

S. White, P. Searle, A. Lovering, 2001, Journal of molecular biology.

A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984].

N. James, L. Young, P. Searle, 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

THE STRUCTURE OF ESCHERICHIA COLI NITROREDUCTASE COMPLEXED WITH NICOTINIC ACID

S. White, P. Searle, A. Lovering, 2001 .

Metallothionein gene regulation.

P. Searle, 1987, Biochemical Society Transactions.

Oxygen‐insensitive nitroreductase E. coli NfsA, but not NfsB, is inhibited by fumarate

S. White, P. Searle, E. Hyde, 2022, Proteins.

The structures of E. coli NfsA bound to the antibiotic nitrofurantoin; to 1,4-benzoquinone and to FMN

P. Searle, A. Christofferson, E. Hyde, 2021, The Biochemical journal.

Inhibition of NF-kappaB enhances the cytotoxicity of virus-directed enzyme prodrug therapy and oncolytic adenovirus cancer gene therapy.

D. Kerr, P. Searle, D. Palmer, 2005, Gene therapy.